Standard Biotools Inc - Asset Resilience Ratio
Standard Biotools Inc (LAB) has an Asset Resilience Ratio of 32.95% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See LAB working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2006–2025)
This chart shows how Standard Biotools Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see balance sheet size of Standard Biotools Inc.
Liquid Assets Composition Over Time
This chart breaks down Standard Biotools Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore investment intensity of Standard Biotools Inc to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $206.69 Million | 32.95% |
| Total Liquid Assets | $206.69 Million | 32.95% |
Asset Resilience Insights
- Very High Liquidity: Standard Biotools Inc maintains exceptional liquid asset reserves at 32.95% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Standard Biotools Inc Industry Peers by Asset Resilience Ratio
Compare Standard Biotools Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Medtronic plc
SA:MDTC34 |
Medical Devices | 7.82% |
|
Demant A/S
CO:DEMANT |
Medical Devices | -2.59% |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223 |
Medical Devices | 0.84% |
|
Jafron Biomedical Co Ltd
SHE:300529 |
Medical Devices | 34.37% |
|
Sinocare Inc
SHE:300298 |
Medical Devices | 3.53% |
|
Emvision Medical Devices Ltd
AU:EMV |
Medical Devices | 0.06% |
|
Theradiag SA
PA:ALTHE |
Medical Devices | 15.59% |
|
Biosynex
PA:ALBIO |
Medical Devices | 3.35% |
Annual Asset Resilience Ratio for Standard Biotools Inc (2006–2025)
The table below shows the annual Asset Resilience Ratio data for Standard Biotools Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 12.22% | $69.36 Million | $567.75 Million | -8.38pp |
| 2024-12-31 | 20.60% | $126.15 Million | $612.34 Million | +1.04pp |
| 2023-12-31 | 19.56% | $63.19 Million | $323.07 Million | -22.92pp |
| 2022-12-31 | 42.47% | $165.78 Million | $390.31 Million | +32.14pp |
| 2021-12-31 | 10.34% | $28.45 Million | $275.21 Million | +3.96pp |
| 2020-12-31 | 6.37% | $20.70 Million | $324.76 Million | -9.50pp |
| 2019-12-31 | 15.87% | $42.02 Million | $264.81 Million | -9.72pp |
| 2018-12-31 | 25.59% | $77.72 Million | $303.65 Million | +10.63pp |
| 2017-12-31 | 14.97% | $43.01 Million | $287.35 Million | +0.13pp |
| 2016-12-31 | 14.83% | $45.45 Million | $306.39 Million | -2.92pp |
| 2015-12-31 | 17.75% | $65.86 Million | $371.06 Million | -2.27pp |
| 2014-12-31 | 20.02% | $81.59 Million | $407.56 Million | -21.96pp |
| 2013-12-31 | 41.98% | $49.08 Million | $116.92 Million | +23.20pp |
| 2012-12-31 | 18.78% | $21.36 Million | $113.73 Million | -31.53pp |
| 2011-12-31 | 50.32% | $39.91 Million | $79.33 Million | +38.84pp |
| 2007-12-31 | 11.48% | $6.29 Million | $54.78 Million | +10.11pp |
| 2006-12-31 | 1.37% | $500.00K | $36.49 Million | -- |
About Standard Biotools Inc
Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments. Its proteomics and genomics include instruments, consum… Read more